EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY-NC 4.0

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial

Elisabeth Bahlmann-Kroll, Sebastian Häckl, Stefanie Kramer, Vera Christine Wulfmeyer, Julian Glandorf, Jessica Kaufeld, Armin Koch, Dagmar Hartung, Bernhard M W Schmidt, Kai Schmidt-Ott, Roland Schmitt

BMJ Open · 2024

DOI: 10.1136/bmjopen-2024-088317 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BMJ Open, 2024. Verfasst von Elisabeth Bahlmann-Kroll und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary condition that causes the formation of cysts primarily in the kidneys. The continuous growth of multiple cysts leads to the destruction of functional parenchyma, which may progress to end-stage kidney disease. Tolvaptan is the only drug specifically approved for slowing down the progression of ADPKD. Sodium-glucose transporter 2 inhibitors might provide additional benefits but there is currently no information on safety and outcome effects of SGLT2i in patients with ADPKD, as these patients were excluded in SGLT2i trials. In particular, there has been speculation that SGLT2i might increase cyst growth and accelerate the loss of kidney function in ADPKD. The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring the total kidney volume and the loss of kidney function. Methods and analysis This is an investigator-initiated, double-blind, single-centre, placebo-controlled, randomised clinical trial including patients with rapidly progressive ADPKD (n=44). Participants will be randomly allocated (1:1) to receive a daily dose of either empagliflozin (10 mg/day) or placebo for 18 months. Patients will be stratified according to concomitant tolvaptan use. The primary endpoint is the progression of cystic kidney growth by monitoring MRI-based changes in total kidney volume and the secondary endpoint is the change in glomerular filtration rate. Additional endpoints include changes in copeptin levels, albuminuria and blood pressure. Ethics and dissemination The protocol has been approved by the German Federal Institute for Drugs and Medical Devices (BfArM) after review by the independent ethics committee Landesarztekammer Rheinland-Pfalz. Participation in this study will be voluntary and informed consent will be obtained. Regardless of the outcome, the results will be disseminated through a peer-reviewed international medical journal. Trial registration numbers EU-CT number 2023-505890-34-00, NCT06391450 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsTolvaptanRandomized Controlled Trials as TopicHumansDouble-Blind MethodGlomerular Filtration RateDisease ProgressionAdultAntidiuretic Hormone Receptor AntagonistsMaleKidneyFemale

Stichwörter der Autor:innen

Adult nephrologyNEPHROLOGYNephrology

Substanzen

GlucosidesempagliflozinBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsTolvaptanAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
  • Institute for Biostatistics, Hannover Medical School, Hannover, Germany.
  • Institute for Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
  • Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany schmitt.roland@mh-hannover.de.
  • Department of Nephrology and Hypertension, University Hospital Schleswig Holstein, Kiel, Germany.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Bahlmann-Kroll, E., Häckl, S., Kramer, S., Wulfmeyer, V. C., Glandorf, J., Kaufeld, J., Koch, A., Hartung, D., Schmidt, B. M. W., Schmidt-Ott, K., & Schmitt, R. (2024). Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. BMJ Open. https://doi.org/10.1136/bmjopen-2024-088317

Vancouver

Bahlmann-Kroll E, Häckl S, Kramer S, Wulfmeyer VC, Glandorf J, Kaufeld J, et al. Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. BMJ Open. 2024. doi:10.1136/bmjopen-2024-088317

BibTeX
@article{BahlmannKroll2024,
  author = {Bahlmann-Kroll, Elisabeth and Häckl, Sebastian and Kramer, Stefanie and Wulfmeyer, Vera Christine and Glandorf, Julian and Kaufeld, Jessica and Koch, Armin and Hartung, Dagmar and Schmidt, Bernhard M W and Schmidt-Ott, Kai and Schmitt, Roland},
  title = {Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial},
  journal = {BMJ Open},
  year = {2024},
  doi = {10.1136/bmjopen-2024-088317}
}
Kostenlos starten →